First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

• Published in: Investigational new drugs 2015-12, Vol.33 (6), p.1232-1241
• Main Authors: Berglund, Åke, Ullén, Anders, Lisyanskaya, Alla, Orlov, Sergey, Hagberg, Hans, Tholander, Bengt, Lewensohn, Rolf, Nygren, Peter, Spira, Jack, Harmenberg, Johan, Jerling, Markus, Alvfors, Carina, Ringbom, Magnus, Nordström, Eva, Söderlind, Karin, Gullbo, Joachim
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Alkylation - drug effects; Alkylation - physiology; Antineoplastic Agents, Alkylating - administration & dosage; Antineoplastic Agents, Alkylating - adverse effects; Cancer therapies; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug dosages; Female; Hematologic Diseases - chemically induced; Humans; Informed consent; Lung cancer; Male; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Melflufen; Melphalan - administration & dosage; Melphalan - adverse effects; Melphalan - analogs & derivatives; Melphalan flufenamide; Middle Aged; Multiple myeloma; Neoplasms - diagnosis; Neoplasms - drug therapy; Oncology; Ovarian cancer; Patients; Peptide Hydrolases - metabolism; Pharmacology/Toxicology; Phase I Studies; Phenylalanine - administration & dosage; Phenylalanine - adverse effects; Phenylalanine - analogs & derivatives; Prospective Studies; Toxicity; Tumors
• ISSN: 0167-6997; 1573-0646; 1573-0646
• DOI: 10.1007/s10637-015-0299-2

Summary Purpose Melflufen (melphalan flufenamide, previously designated J1) is an optimized and targeted derivative of melphalan, hydrolyzed by aminopeptidases overexpressed in tumor cells resulting in selective release and trapping of melphalan, and enhanced activity in preclinical models. Methods This was a prospective, single-armed, open-label, first-in-human, dose-finding phase I/IIa study in 45 adult patients with advanced and progressive solid tumors without standard treatment options. Most common tumor types were ovarian carcinoma ( n  = 20) and non-small-cell lung cancer (NSCLC, n  = 11). Results In the dose-escalating phase I part of the study, seven patients were treated with increasing fixed doses of melflufen (25–130 mg) Q3W. In the subsequent phase IIa part, 38 patients received in total 115 cycles of therapy at doses of 30–75 mg. No dose-limiting toxicities (DLTs) were observed at 25 and 50 mg; at higher doses DLTs were reversible neutropenias and thrombocytopenias, particularly evident in heavily pretreated patients, and the recommended phase II dose (RPTD) was set to 50 mg. Response Evaluation Criteria In Solid Tumors (RECIST) evaluation after 3 cycles of therapy (27 patients) showed partial response in one (ovarian cancer), and stable disease in 18 patients. One NSCLC patient received nine cycles of melflufen and progressed after 7 months of therapy. Conclusions In conclusion, melflufen can safely be given to cancer patients, and the toxicity profile was as expected for alkylating agents; RPTD is 50 mg Q3W. Reversible and manageable bone marrow suppression was identified as a DLT. Clinical activity is suggested in ovarian cancer, but modest activity in treatment of refractory NSCLC.